• Thu, June 8, 2017
  • Mon, June 12, 2017
  • Tue, June 6, 2017
  • Fri, June 9, 2017
  • Wed, June 7, 2017
  • Tue, June 13, 2017

Matthew Luchini Upgraded (BLUE) to Buy and Increased Target to $108 on, Jun 6th, 2017

Matthew Luchini of BMO Capital, Upgraded "bluebird bio, Inc." (BLUE) to Buy and Increased Target from $61 to $108 on, Jun 6th, 2017.

Matthew has made no other calls on BLUE in the last 4 months.



There is 1 other peer that has a rating on BLUE. Out of the 1 peers that are also analyzing BLUE, all agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jason McCarthy of "Maxim Group" Downgraded from Strong Buy to Hold on, Tuesday, February 28th, 2017